NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/19/2025
Back to search
Official data from USPTO
ELATIVE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
06/20/2025
Trademark type
Combined
Nice classes
5, 42
Filing date
06/25/2021
Registration date
09/27/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/27/2022
Last transaction
06/20/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
33
Owner location
FR
Examiner
GILLES, DEBORAH
Law office
M10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized word "ELATIVE" with the letters "ELATI" and the last letter "E" in blue and the letter "V" in orange.
Holders and representatives
Holders
GENFIT
Representatives
Ronald M. Kachmarik Cooper Legal Group, LLC
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the prevention and treatment of liver diseasescholesterol diseasesmetabolic diseasesgastroenterological diseasesinflammatory diseasesauto-immune diseases and cancer diseases; chemical preparations for medical or pharmaceutical usenamely for the prevention and treatment of liver diseasescholesterol diseasesmetabolic diseasesgastroenterological diseasesinflammatory diseasesauto-immune diseases and cancer diseases; organic biological preparations for medical or pharmaceutical usenamely for the prevention and treatment of liver diseasescholesterol diseasesmetabolic diseasesgastroenterological diseasesinflammatory diseasesauto-immune diseases and cancer diseases; diagnostic preparations for medical use; diagnostic reagents for medical use
Class 42
Scientific research for medical purposes; pharmaceutical research and development services; conducting clinical trials for others for pharmaceutical productsin particular conducting clinical trials for others for determining the efficacy and safety of elafibranor; conducting clinical trials for others to determine the efficacy and safety of pharmaceutical products in the treatment of primary biliary cholangitis (PBC); conducting scientific studies and analyses in the field of pharmaceuticals and medicines; scientific research and developmentnamely providing informationresults and data relating to scientific or medical research and development of pharmaceutical productsespecially from an online searchable database; medical and scientific researchnamely conducting clinical trials for others; pharmaceutical and biological development and research services for third parties; clinical research for others in the field of pharmaceuticals and medicines; evaluation of the efficacy of pharmaceutical products
Publications
History of USPTO decisions and trademark events.
28 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/14/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/25/2023
FIMP
FINAL DISPOSITION PROCESSED
01/25/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/27/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/27/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
09/27/2022
GPNX
NOTIFICATION PROCESSED BY IB
07/19/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/12/2022
PUBO
PUBLISHED FOR OPPOSITION
07/12/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/29/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
06/29/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/22/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/09/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/08/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/07/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/07/2022
RFNT
REFUSAL PROCESSED BY IB
05/25/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/08/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/04/2022
RFRR
REFUSAL PROCESSED BY MPU
05/04/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/25/2022
CNRT
NON-FINAL ACTION WRITTEN
03/24/2022
DOCK
ASSIGNED TO EXAMINER
03/17/2022
MAFR
APPLICATION FILING RECEIPT MAILED
11/12/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/08/2021
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
11/05/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/28/2021
Continuous trademark protection
Get notified about every new filing that threatens ELATIVE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.